marketsgonewild

Revolutionizing Oncology Clinical Trials: Science 37 and Syapse Join Forces to Accelerate Patient Enrollment

Revolutionizing Oncology Clinical Trials Accelerating Patient Enrollment for the Benefit of Oncology Patients Science 37 and Syapse: A Game-Changing Partnership Oncology clinical trials have long been plagued by slow patient enrollment, leading to delays in the development of innovative treatments and therapies. However, a recent partnership between Science 37 and Syapse is set to revolutionize…

Read More

Get Ready to LOL: Processa Pharmaceuticals Drops the Deets on Q2 2022 Finances and Company Happenings!

Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update PCS12852 on target to complete enrollment by September Expanded efforts to increase enrollment in PCS499 and PCS6422 showing results Exciting news for Processa Pharmaceuticals, Inc. as they announce their second quarter 2022 financial results and provide a corporate update. With PCS12852 on track…

Read More

Cerevel Therapeutics: A Whimsical Tale of a $300 Million Private Offering and a $254 Million Public Offering

Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes What is Cerevel Therapeutics? Cerevel Therapeutics Holdings, Inc. is a company based in Cambridge, Massachusetts that is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. Their mission is to develop innovative treatments for conditions that affect the brain…

Read More

Revolutionizing the Future: AirSculpt Technologies Inc. Unveils Second Quarter 2022 Results and Approves Special Cash Dividend

Welcome to the Future of Body Contouring with AirSculpt Technologies, Inc. Embracing Innovation and Excellence As AirSculpt Technologies, Inc. announces its impressive second quarter results for 2022, it is evident that the company is paving the way for the future of premium body contouring procedures. With a commitment to excellence and innovation, AirSculpt continues to…

Read More

Breaking Bones: Rani Therapeutics’ RT-102 Shakes Up Osteoporosis Treatment with Positive Phase 1 Results!

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis Witty, Conversational Blog Post Article: Hey there, lovely readers! Have you heard the latest buzz in the medical world? Rani Therapeutics has just released some exciting news about their Phase 1 study of RT-102 in treating osteoporosis. And let me tell…

Read More

Christopher Banks: Driving Success with 79% Year-Over-Year Spring Sales Growth and Expansion Plans for Fall 2022

Christopher Banks: Driving Success with 79% Year-Over-Year Spring Sales Growth and Expansion Plans for Fall 2022 MINNEAPOLIS, Aug. 09, 2022 (GLOBE NEWSWIRE) — iMedia Brands, Inc. (“iMedia” or the “Company”) (NASDAQ: IMBI, IMBIL) Christopher & Banks, a 65-year-old iconic brand, has been on a trajectory of success with a remarkable 79% year-over-year growth in net…

Read More

Breaking News: Infinera Successfully Completes $373.75 Million Convertible Senior Notes Offering and Repurchases $300 Million of 2024 Convertible Notes

Breaking News: Infinera Successfully Completes $373.75 Million Convertible Senior Notes Offering and Repurchases $300 Million of 2024 Convertible Notes SAN JOSE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) — Infinera (NASDAQ: INFN) announced today the closing of its previously announced offering of 3.75% convertible senior notes due 2028 (the “2028 Notes”) in a private placement to…

Read More